[go: up one dir, main page]

MX2009006080A - Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades. - Google Patents

Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.

Info

Publication number
MX2009006080A
MX2009006080A MX2009006080A MX2009006080A MX2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A
Authority
MX
Mexico
Prior art keywords
prodrugs
gaba analogs
disease
treating diseases
fibromyalgia
Prior art date
Application number
MX2009006080A
Other languages
English (en)
Inventor
Kenneth C Cundy
Ronald W Barret
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of MX2009006080A publication Critical patent/MX2009006080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para utilizar análogos de GABA y composiciones farmacéuticas de los mismos para el tratamiento de migraña, fibromialgia, esclerosis lateral amiotrófica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva crónica, y composiciones farmacéuticas de profármacos de análogos de GABA útiles para tratar migraña, fibromialgia, esclerosis lateral amiotrófica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos, o enfermedad pulmonar obstructiva crónica.
MX2009006080A 2006-12-08 2007-12-06 Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades. MX2009006080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87356106P 2006-12-08 2006-12-08
PCT/US2007/024944 WO2008073257A1 (en) 2006-12-08 2007-12-06 Use of prodrugs of gaba analogs for treating diseases

Publications (1)

Publication Number Publication Date
MX2009006080A true MX2009006080A (es) 2009-07-14

Family

ID=39186816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006080A MX2009006080A (es) 2006-12-08 2007-12-06 Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (2) US20080161393A1 (es)
EP (1) EP2101752A1 (es)
JP (1) JP2010512314A (es)
CN (1) CN101652133A (es)
AR (1) AR064212A1 (es)
AU (1) AU2007332904A1 (es)
BR (1) BRPI0720252A2 (es)
CA (1) CA2672044A1 (es)
EA (1) EA200970487A1 (es)
MX (1) MX2009006080A (es)
PE (1) PE20081389A1 (es)
TW (1) TW200845959A (es)
WO (1) WO2008073257A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
US8026279B2 (en) * 2003-10-14 2011-09-27 Xenoport, Inc. Crystalline form of γ-aminobutyric acid analog
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2117517B1 (en) * 2007-01-11 2011-06-01 XenoPort, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US8268887B2 (en) * 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
CN102341099A (zh) * 2009-03-03 2012-02-01 什诺波特有限公司 R-巴氯芬前药的持续释放口服剂型
EP2521453B1 (en) * 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
US20130261165A1 (en) * 2010-12-16 2013-10-03 The Mclean Hospital Corporation Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
JP2015529254A (ja) * 2012-09-21 2015-10-05 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法
HK1219268A1 (zh) 2013-02-26 2017-03-31 Xenoport, Inc. 1-(酰氧基)-烷基氨基甲酸酯化合物的制造方法
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
CN107271599A (zh) * 2016-04-08 2017-10-20 上海市刑事科学技术研究院 一种人唾液中地西泮及其代谢物的在线spe lc-ms/ms分析方法
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof
EP3793974A4 (en) * 2018-05-14 2022-05-04 Xgene Pharmaceutical Inc Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
DE112019007341B4 (de) * 2019-06-20 2024-06-13 Hitachi High-Tech Corporation Substanzanalysator und substanzanalyseverfahren
RU2709527C1 (ru) * 2019-07-29 2019-12-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Met-Glu-His-Phe-Pro-Gly-Pro (семакса) для коррекции дисбиоза при хроническом иммобилизационном стрессе
US12147601B1 (en) 2022-04-28 2024-11-19 Snap Inc. Removing eye blinks from EMG speech signals
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
HU224720B1 (en) * 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
BR9708180A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Amoniácidos cíclicos em pontes como agentes farmacêuticos
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6680343B1 (en) * 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
NZ509231A (en) * 1998-07-09 2003-08-29 Warner Lambert Co Use of GABA analogs to treat insomnia
US6490454B1 (en) * 1998-08-07 2002-12-03 Telefonaktiebolaget Lm Ericsson (Publ) Downlink observed time difference measurements
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20040002543A1 (en) * 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1533270A (zh) * 2001-06-11 2004-09-29 ʲŵ�������޹�˾ 具有降低毒性的gaba类似物前药的口服给药剂型
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
EP1446396A1 (en) * 2001-11-08 2004-08-18 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
KR20040081478A (ko) * 2002-01-31 2004-09-21 워너-램버트 캄파니 엘엘씨 이명을 치료하기 위한 알파 2 델타 리간드
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2509615A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
JP2006511604A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
EP1608357A4 (en) * 2003-03-31 2008-03-26 Xenoport Inc TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
MXPA06002619A (es) * 2003-09-12 2006-06-05 Warner Lambert Co Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion.
MXPA06003043A (es) * 2003-09-17 2006-05-31 Xenoport Inc Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba.
MXPA06003396A (es) * 2003-09-25 2006-06-08 Warner Lambert Co Profarmacos de aminoacidos con afinidad por la proteina a 2d.
US8026279B2 (en) * 2003-10-14 2011-09-27 Xenoport, Inc. Crystalline form of γ-aminobutyric acid analog
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
RU2440112C2 (ru) * 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
US20060192353A1 (en) * 2005-02-08 2006-08-31 Schubert Peter J Method of producing a rollover arming signal based on off-axis acceleration
WO2007027477A2 (en) * 2005-08-23 2007-03-08 Xenoport, Inc. Treating vulvodynia using prodrugs of gaba analogs
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
AU2007319851A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
WO2009094563A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
US7868043B2 (en) * 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use

Also Published As

Publication number Publication date
US20120041061A1 (en) 2012-02-16
TW200845959A (en) 2008-12-01
EA200970487A1 (ru) 2009-12-30
JP2010512314A (ja) 2010-04-22
PE20081389A1 (es) 2008-11-19
AU2007332904A1 (en) 2008-06-19
WO2008073257A1 (en) 2008-06-19
EP2101752A1 (en) 2009-09-23
CN101652133A (zh) 2010-02-17
AR064212A1 (es) 2009-03-18
CA2672044A1 (en) 2008-06-19
US20080161393A1 (en) 2008-07-03
BRPI0720252A2 (pt) 2014-01-07

Similar Documents

Publication Publication Date Title
MX2009006080A (es) Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
WO2010022177A3 (en) Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2011106106A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
PH12012500620A1 (en) Compounds
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2009004289A (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
PH12015500301A1 (en) A novel formulation of diclofenac
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
TW200806312A (en) Methods and compositions related to improving properties of pharmacological agents targenting nervous system
MY162499A (en) Methylphenidate-prodrugs, processes of making and using the same
EA200970883A1 (ru) Индолкарбоксамиды как ингибиторы ikk2
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal